Unknown PHASE2 INTERVENTIONAL 1-arm NCT03646968

Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study (SAVE)

Phase II Study to Evaluate the Effectiveness and Safety of Anlotinib Combined With Docetaxel in Progress After First Line Standard Cheomotherapy in Advanced Non-driver Mutation Non- Squamous Non-small Cell Lung Cancer

Sponsor: Yongchang Zhang

Conditions Non-Squamous Non Small Cell Lung Cancer

Interventions Anlotinib and Docetaxel

Updated 8 times since 2018 Last updated: Dec 25, 2023 Started: Aug 1, 2018 Primary completion: Dec 31, 2024 Completion: Jun 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Non-Squamous Non Small Cell Lung Cancer and is currently ongoing. Yongchang Zhang leads this study, which shows 8 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Feb 2026 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jan 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Apr 2022 — Jan 2024 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

Jan 2021 — Apr 2022 [monthly]

Recruiting PHASE2
Apr 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Sep 2018 — Apr 2020 [monthly]

Recruiting PHASE2

First recorded

Aug 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yongchang Zhang

Data source: Hunan Province Tumor Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Changsha, China